Dicerna Pharmaceuticals, Inc. (DRNA)

Oncology Corporate Profile

Stock Performance

4.7600
0.0100

HQ Location

480 Arsenal Street, Building 1, Suite 120
Watertown, MA 2472

Company Description

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas and intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.

Website: http://www.dicerna.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
DCR-MYCRNAi therapeuticHepatocellular carcinoma (HCC)Preclinical

View additional information on product candidates here »

Source: http://www.dicerna.com

Recent News Headlines

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/9/2017 12:17 am

5/9/2017 12:17 am

5/9/2017 12:17 am

5/9/2017 12:17 am

5/9/2017 12:17 am

5/8/2017 12:18 pm

5/8/2017 12:18 pm

5/8/2017 12:18 pm

5/8/2017 12:18 pm

5/8/2017 12:18 pm

5/8/2017 06:18 am

5/8/2017 06:18 am

5/8/2017 06:18 am

5/8/2017 06:18 am

5/1/2017 12:17 pm

4/20/2017 06:17 am

4/20/2017 06:17 am

4/12/2017 06:17 am